Abstract

This narrative review explores the therapeutic shift in Type 2 Diabetes Mellitus (T2DM) management from single-receptor agonists to dual-agonist therapies. While selective GLP-1 receptor agonists like semaglutide have served as a primary treatment standard for metabolic control, the emergence of tirzepatide a "Tw incre tin" targeting both GIP and GLP-1 receptors-presents a new clinical advantage. By simultaneously activating these distinct metabolic pathways, tirzepatide achieves a synergistic effect that enhances insulin secretion and improves adipose tissue regulation beyond the capabilities of single-hormone agents. Clinical comparisons indicate that tirzepatide provides superior reductions in blood glucose and body weight, helping a greater proportion of patients achieve near-normal metabolic levels. Furthermore, the dual-agonist profile shows promising improvements in cardiovascular markers and lipid metabolism with a safety profile characterized primarily by transient gastrointestinal side effects. This paper synthesizes the mechanistic benefits of dual ag onism and evaluates its potential to redefine the gold standard for intensive T2DM therapy.

DOI: doi.org/10.63721/26JADR0103

To Read or Download the Article  PDF